BCL2L1 and neoplasm: In a range of hematological and solid cancers, MCL-1 has been implicated in tumor formation, cell survival, and treatment resistance, including resistance to BCL-XL and BCL-2 targeting [137,154,155,156,157,158,159,160,161].